Export Publications

Exporter les publications affichées :
Nombre de documents


Patrizia Giannoni

Article dans une revue13 documents

  • Kévin Baranger, Patrizia Giannoni, Stéphane Girard, Sarah Girot, Florence Gaven, et al.. Chronic treatments with a 5-HT4 receptor agonist decrease amyloid pathology in the entorhinal cortex and learning and memory deficits in the 5xFAD mouse model of Alzheimer's disease. Neuropharmacology, Elsevier, 2017, 126, pp.128-141. 〈10.1016/j.neuropharm.2017.08.031〉. 〈hal-01799428〉
  • Farron Mcintee, Patrizia Giannoni, Steven Blais, George Sommer, Thomas Neubert, et al.. In vivo Differential Brain Clearance and Catabolism of Monomeric and Oligomeric Alzheimer's Aβ protein. Frontiers in Aging Neuroscience, Frontiers, 2016, 8, 〈10.3389/fnagi.2016.00223〉. 〈hal-01705732〉
  • Margarita Arango-Lievano, Patrizia Giannoni, Sylvie Claeysen, Nicola Marchi. Longitudinal in vivo imaging of the cerebrovasculature: relevance to CNS diseases. Journal of visualized experiments : JoVE, JoVE, 2016. 〈hal-01792491〉
  • Silvia Fossati, Patrizia Giannoni, Maria Solesio, Sarah Cocklin, Erwin Cabrera, et al.. The carbonic anhydrase inhibitor methazolamide prevents amyloid beta-induced mitochondrial dysfunction and caspase activation protecting neuronal and glial cells in vitro and in the mouse brain. Neurobiology of Disease, Elsevier, 2016, 86, pp.29-40. 〈10.1016/j.nbd.2015.11.006〉. 〈hal-01997866〉
  • Patrizia Giannoni, Margarita Arango-Lievano, Ines Das Neves, Marie-Claude ă Rousset, Kévin Baranger, et al.. Cerebrovascular pathology during the progression of experimental ă Alzheimer's disease. Neurobiology of Disease, Elsevier, 2016, 88, pp.107-117. 〈10.1016/j.nbd.2016.01.001〉. 〈hal-01477817〉
  • Christophe Rochais, Cédric Lecoutey, Florence Gaven, Patrizia Giannoni, Katia Hamidouche, et al.. Novel Multitarget-Directed Ligands (MTDLs) with Acetylcholinesterase (AChE) Inhibitory and Serotonergic Subtype 4 Receptor (5-HT 4 R) Agonist Activities As Potential Agents against Alzheimer’s Disease: The Design of Donecopride. Journal of Medicinal Chemistry, American Chemical Society, 2015, 58 (7), pp.3172-3187. 〈10.1021/acs.jmedchem.5b00115〉. 〈hal-02043873〉
  • Sylvie Claeysen, Joël Bockaert, Patrizia Giannoni. Serotonin: a new hope in Alzheimer's disease?. ACS Chemical Neuroscience, American Chemical Society (ACS), 2015. 〈hal-01792388〉
  • Sylvie Claeysen, Patrizia Giannoni. Serotonin type 4 receptor dimers. Methods in Cell Biology, Elsevier, 2013. 〈hal-01792387〉
  • Patrizia Giannoni, Florence Gaven, Dimitri De Bundel, Kevin Baranger, Evelyne Marchetti-Gauthier, et al.. Early administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer’s disease. Frontiers in Aging Neuroscience, Frontiers, 2013, 5, 〈10.3389/fnagi.2013.00096〉. 〈hal-01703910〉
  • Patrizia Giannoni. Alzheimer culprits: cellular crossroads and interplay. Cellular Signalling, Elsevier, 2012. 〈hal-01792371〉
  • Patrizio Blandina, Leonardo Munari, Patrizia Giannoni, Chiara Mariottini, Maria Passani. HISTAMINE NEURONAL SYSTEM AS THERAPEUTIC TARGET FOR THE TREATMENT OF COGNITIVE DISORDERS. Future Neurology, Future Medicine, 2010. 〈hal-01793879〉
  • Maria Beatrice Passani, Corrado Bucherelli, Elisabetta Baldi, Patrizio Blandina, Patrizia Giannoni. Histamine in the brain: Beyond sleep and memory. Biochemical Pharmacology, Elsevier, 2007, 73 (8), pp.1113 - 1122. 〈10.1016/j.bcp.2006.12.002〉. 〈hal-01762502〉
  • Gabriele Cenni, Patrizio Blandina, Ken Mackie, Daniele Nosi, Lucia Formigli, et al.. Differential effect of cannabinoid agonists and endocannabinoids on histamine release from distinct regions of the rat brain. European Journal of Neuroscience, Wiley, 2006, 24 (6), pp.1633 - 1644. 〈10.1111/j.1460-9568.2006.05046.x〉. 〈hal-01764807〉